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A B S T R A C T
A delivery system based on poly(lactic-co-glycolic acid) polymer (PLGA) microparticles has been developed for
parenteral administration of the local anesthetic prilocaine in its free base form. Both drug-free and drug-loaded
microparticles, prepared by a double-emulsion-evaporation method, were characterized for mean size by Laser
Diffraction Analysis, while their morphology was investigated by scanning electron microscopy. The preparation
technique allowed obtainment of homogeneous microparticles of about 25 µm diameter, suitable for sub-
cutaneous administration. The encapsulation efficiency, determined by both direct and indirect methods, was
around 36–38%. Differential Scanning Calorimetry was used to characterize the solid state of the raw materials,
assess drug-polymer compatibility and miscibility and highlight possible modifications of the components in-
duced by the preparation method. In vitro release studies showed a sustained release profile, with about 80% of
drug released after the first 24 h. The anesthetic effect of the formulation was evaluated in vivo on rats, ac-
cording to the test of cutaneous trunci muscle reflex. Administration of prilocaine base as PLGA microparticles
allowed to significantly enhance both extent (60% AUC increase) and duration (100% increase) of the anesthetic
effect in the animal model, in comparison with the equivalent dose of prilocaine hydrochloride aqueous solution.
1. Introduction
Local anesthetic agents are widely used for the control of acute and
chronic pain, particularly in dental practice and in surgery. Although
several new molecules have been developed over the last years, some
critical drawbacks still remain to be solved in order to achieve a more
effective therapeutic use of these drugs. In particular, drug parenteral
administration for injection requires a sufficient aqueous solubility,
which is generally achieved by the use of their hydrochloride form. On
the other hand, this often implies a fast removal of the drug from the
site of injection, reinforced by the vasodilator activity shown by many
local anesthetics. This generally implies an effect limited in terms of
duration and intensity, thus requiring high drug concentrations or re-
peated injections. The co-administration of a vasoconstrictor, generally
epinephrine, is the most common approach to overcome this incon-
venience and prolong the duration of the anesthetic action. However,
the use of vasoconstrictors presents different drawbacks. First of all, it is
not advisable for many patients, such as individuals with high blood
pressure, by-pass surgery, prior myocardial infarction, angina, un-
controlled diabetics, uncontrolled thyroid disorders or treated with
tricyclic anti-depressives (Perusse et al., 1992). Secondly, solutions
containing vasoconstrictors are more acidic, primarily due to the need
of using anti-oxidant preservatives, such as sodium metabisulphite;
consequently, their use is commonly associated with major pain and
patient discomfort during the injection process, due to the reduced pH
(Kramp et al., 1999). Furthermore, vasoconstrictors have been shown to
interfere with pulpal blood flow by reducing the arterioles and venules
diameter, possibly causing pulpitis (Odor et al., 1994, Yu et al., 2002).
Therefore, there are several reasons to consider the potential ad-
vantages of developing innovative formulations, able to enhance the
therapeutic efficacy of anesthetic drugs in terms of both duration and
intensity of the effect, without the employment of vasoconstrictors.
Over the last years, several technological approaches have been in-
vestigated in order to overcome these limitations, designed to enhance
and prolong the therapeutic effect of local anesthetics and also improve
their safety profile, reducing their dosage and dose-related toxicity (de
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Paula et al., 2010). These include complexation with cyclodextrins
(Karashima et al., 2007; de Araujo et al., 2008; Jug et al., 2010;
Bragagni et al., 2010a; Cereda et al., 2012) or entrapment in colloidal
vesicles (Mura et al., 2007; Elsaie and Bauman, 2008; Bragagni et al.
2010b; Tofoli et al., 2011; Tong et al., 2014) or in micro or nano-
particles (Grillo et al., 2010, Melo et al., 2014).
Prilocaine is an amino-amide-type local anesthetic widely used as
hydrochloride salt for intravenous (i.v.) regional anesthesia and in
dentistry. However, its high water solubility gives rise to a fast removal
from the tissues by the bloodstream, thus reducing the duration of the
anesthetic effect and making it necessary repeated injections to achieve
an adequately long pain relief (Malamed, 2012). In a previous work we
tested different types of polylactic acid (PLA) polymers for the pre-
paration of microparticles loaded with prilocaine hydrochloride, in-
tended to obtain a controlled and prolonged delivery of the drug
(Bragagni et al., 2013).
However, the therapeutic outcome of prilocaine base should po-
tentially be more effective than the corresponding hydrochloride form,
being the non-ionized form more lipophilic and more permeable
through the biologic membranes. Nevertheless, the very low aqueous
solubility and limited stability of the drug base form strongly restrict its
use, giving rise to problems in the preparation of classical parenteral
formulations. In fact, no parenteral formulations of prilocaine base are
currently available on the market.
Therefore, as a continuation of our studies, in the present work we
have explored the possibility of preparing biodegradable micro-
particles, suitable for parenteral administration, loaded with prilocaine
in its base form, focused to improve the drug bioavailability and ther-
apeutic effectiveness. Poly(lactic-co-glycolic acid) polymer (PLGA) was
selected as polymeric matrix, considering the extensive evidences at-
testing its safety in use, high biocompatibility, with generation of a very
mild tissue reaction, and its ability to provide a controlled drug release
(Danhier et al., 2012; Pandey and Jain, 2015). Positive results on the
ability of PLGA-microparticle formulations in entrapping and properly
modulating the release of a variety of drugs, included local anesthetics
such as bupivacaine (Le Corre et al., 2002), lidocaine (Klose et al.,
2008) or prilocaine (Delplace et al., 2012), have been reported. In
particular, the factors influencing the release of prilocaine base from
PLGA microparticles have recently been investigated (Gasmi et al.,
2015). However, at the best of our knowledge, no in vivo studies have
been performed until now to evaluate the actual therapeutic effective-
ness of such prilocaine base parenteral delivery systems.
In the present study, prilocaine-loaded PLGA microparticles were
prepared by a double emulsion method and fully characterized in terms
of dimensions, homogeneity, morphology, drug encapsulation effi-
ciency, and in vitro drug release behavior. The duration and intensity of
the anesthetic effect of the developed formulation was evaluated in vivo
by subcutaneous injection to rats, using the block of Cutaneous Trunci
Muscle Reflex (CTMR) as a model of infiltration anesthesia, in com-
parison with the corresponding aqueous solutions of prilocaine hydro-
chloride salt.
2. Materials and methods
2.1. Materials
Poly(D,L-lactic-co-glycolic acid) polymer (PLGA, Resomer RG504H,
50:50 lactic acid-glycolic acid) was purchased from Boehringer
Ingelheim (Ingelheim, Germany). Polyvinyl alcohol (PVA), di-
chloromethane, prilocaine hydrochloride (PRL.HCl), and prilocaine free
base (PRL) were purchased from Sigma Aldrich (Spain). Water was
obtained from a Milli-Q water purification system (Millipore, Billerica,
MA, USA). Phosphate buffer solution 0.1 M pH 7.4 was prepared ac-
cording to Eur. Pharm. 7th Ed. All others chemicals and solvents used in
this study were of analytical reagent grade.
2.2. Preparation of microparticles
Drug-free and drug-loaded microparticles were prepared by a water-
in-oil-in-water (W1/O/W2) double emulsion evaporation method
(Klose et al., 2006). Drug-loaded microparticles were prepared by
adding 2mL of a suspension of 115.5 mg of prilocaine (0.050–0.100 µm
sieve granulometric fraction) in distilled water into a solution of PLGA
(850mg) in dichloromethane (20mL) and emulsifying under stirring
for 5min at 24,000 rpm with a high-speed homogenizer (Ultra-Turrax
T25 Basic, IKA-Werke GmbH, Staufen, Germany). This primary W1/O
emulsion was added to 50mL of an outer aqueous solution of PVA (1%
w/w) and submitted for 30min to paddle stirring (Eurostar digital, IKA,
Germany) at 800 rpm in order to obtain a stable double-emulsion W1/
O/W2. The system was then left under stirring at 200 rpm for further
3.5 h to completely remove the organic solvent. Microparticles were
separated by filtration (TCTP membrane filter, polycarbonate, pore size
10 µm, Merck Millipore), rinsed three times with deionized water and
finally freeze-dried (Flexi-Dry MPTM, FTS® Systems, NY, USA). Drug-
free microparticles were obtained according to the same procedure,
without prilocaine.
The percentage yield of microparticle production was determined
using the following equation:
=
+ ×
%Yield [weight ofmicroparticles/(weight of polymer
weight of the drug)] 100
2.3. Morphological and size analyses of microparticles
The morphological properties of microparticles, before and after
drug release tests, were investigated by SEM microscopy (JEOL EOS
6335F microscope, Tokyo, Japan). Before analysis, samples were gold-
coated under vacuum (K550X ion sputter, Emitech, UK) 3min at
25mA.
Mean diameter and polydispersity index (PDI) of the microparticles
were determined by using a Laser Diffraction Particle Size Analyzer
(S3500 Microtrac, Meerbusch, Germany). Samples were prepared by
suspending about 5mg of microparticles in 3mL of deionized water and
sonicating 1min in a water bath to prevent aggregation phenomena.
Each analysis was carried out in triplicate.
2.4. Encapsulation efficiency and drug loading capacity of microparticles
The drug encapsulation efficiency was determined by both an in-
direct and a direct method.
For the indirect method, the external water phase (W2) was re-
covered after microparticle filtration and the concentration of the drug
dissolved was spectrometrically assayed at 240 nm. An aqueous solu-
tion of PVA 1% w/w was used as blank and for the preparation of the
calibration curve (R2=0.9998). Encapsulation efficiency (EE%) was
calculated using the following equation:
= − ×%EE (W W /W ) 100tot free tot
where Wfree is the amount of free drug in the aqueous phase after
microparticle separation and Wtot the total amount of drug initially
used.
For the direct method, an accurately weighed sample of loaded
microparticles (20mg) was dissolved in dichloromethane (2 mL). The
drug was then extracted in HCl 0.1 M, using aliquots of 5mL and
maintaining the suspension under stirring. The procedure was repeated
four times and the drug was spectrometrically assayed at 230 nm in
every aliquot. The blank used for the analyses and for the calibration
curve (R2=0.9982) contained all microparticle materials except the
drug, since it was prepared with the same extraction procedure using
drug-free microparticles. The efficiency of the extraction procedure was
verified using dichloromethane suspensions containing known amounts
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of pure drug and submitted to the same extraction procedure. The
average yield of the drug extraction procedure was 96.7 ± 0.4%
(n=3).
Encapsulation efficiency (EE%) was calculated according to the
following equation:
= ×EE% (W /W ) 100ins tot
where Wins was the amount of drug inside the microparticles, and Wtot
the total amount of drug initially used.
Drug loading capacity (LC%) was determined using the following
equation:
= ×LC% (W /W ) 100ins MPtot
where Wins was the amount of drug inside the microparticles, and
WMPtot the total weight of microparticles.
All determinations were carried out in triplicate.
2.5. In vitro drug release studies
In vitro experiments were performed in order to simulate and ex-
amine the drug release behavior after the formulation injection. Briefly,
weighed microparticle samples (50mg) were put in vials with 3mL of
pH 7.4 phosphate buffer, hermetically closed, and horizontally shaken
at 50 S/min and 37 ± 2 °C in a Clifton NES-28 shaker bath (Nickel-
Electro Ltd., Weston-super-Mare, UK). At given times, 2 mL samples
were withdrawn and replaced with an identical volume of fresh
medium. The drug amount in the samples was quantified by UV–VIS at
230 nm, using a pH 7.4 phosphate buffer solution as blank and for the
calibration curve (R2=0.9992). The progressive dilution of the medium
was calculated. Release experiments were carried out in triplicate.
At the end of drug release tests, microparticles were recuperated
and dried in oven at 40 °C overnight. Part of these microparticles was
used for observation by SEM microscopy. The remaining part was uti-
lized for quantification of the unreleased drug: an accurately weighed
sample of microparticles was dissolved in dichloromethane and ex-
tracted in acidic aqueous solution as above described (par. 2.4., direct
method).
2.6. Differential scanning calorimetry (DSC)
Drug alone, PLGA, drug-free and drug-loaded microparticles were
analyzed by differential scanning calorimetry (DSC 820, Mettler
Toledo, Switzerland, endowed with a refrigerated cooling system
TC100, Huber, Germany). Exactly weighed samples (about 5mg) were
analyzed in pierced aluminum pans. The pure drug was analyzed at a
heating rate of 10 °Cmin-1 in a 20–200 °C temperature range. For the
analyses of pure polymer, drug-free and drug-loaded microparticles, a
heat-cool-heat loop was carried out. The thermal phenomena were
measured in the second heating cycle of the loop: heating from 20 °C to
80 °C; 2min isothermal at 80 °C; quenching from 80 °C to 20 °C; 2min
isothermal at 20 °C; heating from 20 °C to 200 °C. Both heating rate and
quenching rate were 10 °Cmin-1.
2.7. In vivo studies
Male Sprague-Dawley Rats (Envigo, Varese, Italy) weighing about
300–350 g at the start of the experimental procedure, were used.
Animals were housed in CeSAL (Centro Stabulazione Animali da
Laboratorio, University of Florence) and used no less than one week
after their arrival. Ten rats were housed per cage (size 26×41 cm);
animals were kept at 23 ± 1 °C, with a 12 h light/dark cycle (light at
7 a.m), and fed on a standard laboratory diet and tap water ad libitum.
All manipulations of the animals were performed complying with the
European Parliament Directive 2010/63/EU and the European Union
Council (22/09/2010) on the protection of animals used for scientific
aims. The ethical policy of Florence University complies with the Guide
for Care and Use of Laboratory Animals of US National Institutes of
Health (NIH Publication No. 85–23, revised 1996; University of
Florence assurance number: A5278-01). Formal approval to perform
the experiments was given by the Animal Subjects Review Board of the
University of Florence. Experiments involving animals have been per-
formed according to ARRIVE guidelines (McGrath and Lilley, 2015). All
efforts were made to minimize animal suffering and to reduce the
number of animals used. The experiments were done on handled ani-
mals familiarized with the experimental environment and procedures.
The lack of stress behavior (immobilization, absence of exploratory
behavior in an open field environment, recurrent defecation, etc.), the
absence of a dorsal contractile response to the non-noxious stroking and
a significant response to noxious stimuli were considered as sufficient
features. As characteristic response to a noxious pinprick, the Cuta-
neous Trunci Muscle Reflex (CTMR) was investigated. It is defined as
the reflex movement of the skin over the back generated by convulsive
movements of lateral thoracic-spinal muscles as a consequence of a
local stimulus. Inhibition of CTMR was utilized as a model of infiltra-
tion anesthesia, according to the method of Khodorova and Strichartz
(2000). Each anesthetic formulation was administered subcutaneously
in 0.6mL solution. The injections produced a round wheal (about 2 cm)
of the skin, that was delineated with ink. Six pinpricks were then ap-
plied inside this zone, and the number to which the rat failed to respond
was measured. The intensity of the local anesthetic effect was quanti-
fied on the basis of the number of times the pinprick failed to provoke a
reaction. The total lack of 6 responses was considered as 100% CTMR
block (100% of maximum possible effect [MPE]). Measurements (6
pinpricks each) were performed every 15min up to a full recovery was
attained. Each dose was always administered over a naive part of the rat
clipped back. Six areas into the rat back were used to test different
preparations. All substances were solubilized or suspended in Phos-
phate Buffered Saline solution (PBS, pH 7.4) and administered in a
volume of 0.6 mL. Aqueous solutions of prilocaine hydrochloride were
initially administered at different concentrations (0.05%, 0.1%, 0.3%
and 0.5% w/v), to evaluate the dose–effect response of the drug. The
drug-loaded microparticles were administered at drug concentrations of
0.1% and 0.3%, chosen because they gave the best results in pre-
liminary experiments. The vehicle (PBS) was used as control. Drug-free
microparticles were used as blank and administered at the same con-
centration as in the corresponding drug-loaded formulation.
Behavioral measurements were performed on 6 rats for each treat-
ment. Results were expressed as means ± s.e.m. and the analysis of
variance was performed by one way ANOVA. A Bonferroni's significant
difference procedure was used as post-hoc comparison. P < 0.05 or
0.01 were considered significant. Data were analyzed with the Origin 9
software (OriginLab, Northampton, USA).
3. Results and discussion
3.1. Characterization of drug-free and drug-loaded microparticles
Preliminary experiments, performed by varying the theoretical drug
loading from 3 to 18% (28.9–169.4mg drug and 771.6–935.0 mg
PLGA), allowed selection of the best drug:polymer w/w ratio to use for
microparticle preparation (115.5mg drug and 850.0mg PLGA, corre-
sponding to a theoretical 12% drug loading), on the basis of the highest
entrapment efficiency.
SEM analysis was employed to investigate and compare the mor-
phological appearance of drug-free and drug-loaded microparticles
(Fig. 1).
Drug-free microparticles (Fig. 1a) exhibited a regular spherical
shape and smooth surface, without any evidence of pores or cavities,
and a relatively homogeneous distribution in terms of mean dimensions
was observed. Interestingly, the aspect of drug-loaded microparticles
(Fig. 1b) was different. In fact, even though their mean dimensions
were rather similar to those of drug-free microparticles, the particles
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showed a partially collapsed spherical shape. This effect, not previously
observed for other kinds of prilocaine-loaded PLGA microparticles
prepared by an oil-in-water (O/W) solvent/extraction/evaporation
technique (Delplace et al., 2012; Gasmi et al., 2015), was then attrib-
uted to the different preparation method used in the present study
(water-in-oil-in-water (W/O/W) solvent evaporation method) (Jeyanthi
et al., 1996; Freitas et al., 2005). In particular, it could be reasonably
hypothesized that the slow solvent removal process allowed to point
out a plasticizing effect of prilocaine towards the polymer (Delplace
et al., 2012). In fact such phenomenon was not observed for the cor-
responding drug-free microparticles.
The drug appeared to be completely dissolved within the polymeric
matrix, according to the reported prilocaine saturation solubility in the
PLGA phase of about 15% (Delplace et al., 2012, Gasmi et al., 2015).
As expected, upon 72 h exposure to the release medium, the surface
of microparticles became much more rough and porous, as a con-
sequence of both drug release and matrix erosion phenomena (Fig. 1c).
Laser Diffraction Particle Size analysis indicated a monomodal dis-
tribution of particle size for both drug-free and drug-loaded
microparticles and no significant differences were observed between
their mean dimensions, according to the results of SEM analysis. The
mean diameter values were very suitable for subcutaneous injection,
being respectively 24.2 µm (±5.1 µm) and 26.1 µm (± 4.3 µm), and
clearly smaller and more homogeneous than those of previously de-
veloped prilocaine-loaded PLGA microparticles, which were all around
80–90 µm, with an almost large standard deviation of about 38–40%
(Gasmi et al., 2015). Then, the microencapsulation technique proposed
in this paper for prilocaine-base provided not only microparticles with
narrower size dispersion than the existing ones, but also made their
subcutaneous administration easier. In fact, the size lower than 35 µm is
suitable for a 23G needle injection without blockage of the syringe
mechanism (Whitaker et al., 2001).
The direct and indirect methods used for the determination of the
encapsulation efficacy gave comparable results, resulting in EE% values
of 36.0 ± 0.8% (n= 3) and 38.1 ± 0.9% (n= 3), respectively. The
corresponding LC% values were 4.8 ± 0.2% and 5.1 ± 0.2%, re-
spectively.
An optimal percentage yield in the microparticle production of
Fig. 1. SEM pictures of drug-free (a), or prilocaine-loaded PLGA microparticles before (b) or after (c) exposure to pH 7.4 phosphate buffer for 72 h.
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about 90% was obtained.
3.2. In vitro drug release studies
Sink conditions were maintained throughout the experiments, in
virtue of the progressive replacement of the solvent (pH 7.4 phosphate
buffer) with fresh medium. Fig. 2 shows the release behaviour of pri-
locaine from the microparticle formulation. A sustained drug release
was observed with a biphasic trend, characterized by a relatively initial
rapid phase, with the achievement of about 80% drug released after the
first 24 h; this was then followed by a slower release phase, where the
remaining 20% drug was gradually released during the subsequent
48 h. The mathematical model which better represents the release ki-
netic is a first order kinetic (R2=0.936).
In spite of the great success and extended applications of PLGA
microparticles for the development of advanced drug delivery systems,
the underlying mechanisms controlling drug release are still not com-
pletely understood, owing to the numerous involved phenomena and
the different properties of the entrapped drugs (Klose et al., 2006; Klose
et al., 2008; Benéitez et al., 2014; Gasmi et al., 2015; Gasmi et al.,
2016). It has been shown that the drug release profile from PLGA mi-
croparticles is strongly dependent on its initial loading amount: tri-
phasic profiles (high initial release, slow release and final rapid release
phase), or almost mono-phasic profiles (high fast release) were obtained
for low or high loading amounts, respectively, while biphasic profiles,
as that observed in the present case, were instead observed for inter-
mediate values of initial drug loading (Gasmi et al., 2016). Moreover,
both the device geometry and the type of drug can significantly influ-
ence the diffusion kinetic from PLGA-based delivery systems (Klose
et al., 2008). In particular, in the case of prilocaine-loaded PLGA mi-
croparticles, the main mechanisms affecting drug release, related to
both the drug content in the matrix and its basic nature, can be con-
sidered: (i) the different swelling degree and different increase in ma-
trix porosity, upon the progressive drug depletion, with a consequence
mobility increase of the residual drug (Gasmi et al., 2015); (ii) the
quickening of PLGA degradation process, catalyzed by the basic char-
acter of prilocaine free base, and consequent gain in drug mobility
(Siepmann and Goepferich, 2001); (iii) the plasticizing effect of prilo-
caine towards PLGA, which can promote the PLGA molecular mobility,
and, consequently, also the drug mobility (Siepman et al., 2006).
At the end of the release test, microparticles were recuperated and
the drug not released was quantified after disruption of microparticles
in organic solvent. For all the samples the amount of prilocaine ex-
perimentally determined inside the microparticles corresponded to the
expected value based on the drug loading, with a relative error ≤5%.
3.3. DSC studies
The results of DSC analysis of pure components, drug-free and drug-
loaded microparticles are shown in Fig. 3. In the case of pure PLGA and
of microparticles, a heat–cool–heat loop method was utilized, since it
proved to be an useful tool to investigate the compatibility and mis-
cibility of drug-polymer mixtures and to highlight possible modifica-
tions due to the microparticle preparation protocol (Bragagni et al.,
2013; Gasmi et al., 2015).
The thermal curve of pure drug powder exhibited an endothermic
event, starting at about 39 °C and peaked at about 44 °C, corresponding
to the melting of crystalline prilocaine base.
The glass transition of pure PLGA occurred in the 48–55 °C range,
with a midpoint value at 52 °C. No appreciable variations of the glass
transition parameters of PLGA were observed in the DSC curve of drug-
free microparticles, indicating that the experimental conditions em-
ployed for their preparation did not affect the polymer properties. On
the contrary, both onset, offset and midpoint values of PLGA glass
transition were reduced in the drug-loaded microparticles, thus con-
firming the plasticizing effect of prilocaine towards PLGA previously
reported by other authors (Siepmann et al., 2006, Delplace et al., 2012,
Gasmi et al., 2015). On the other hand, the absence of the drug melting
peak in the thermal curve of such sample can be reasonably attributed
to the almost complete dissolution of the drug within the PLGA poly-
meric matrix, as reported by other authors (Delplace et al., 2012, Gasmi
et al., 2015), and as previously observed by SEM analysis. To further
corroborate this, it has been verified that the melting peak of the pure
drug appeared basically unchanged also applying the heat–cool–heat
loop procedure. This proved that the disappearance of prilocaine
melting peak in the thermal curve of drug-loaded microparticles is not
due to its amorphization after the heating and quenching procedure
Fig. 2. Prilocaine (PRL) release profile from PLGA-based microparticles in pH
7.4 phosphate buffer at 37 °C (n=3).
Fig. 3. DSC curves of prilocaine base (PRL), pure PLGA, drug-free and PRL-
loaded PLGA microparticles (MPs).
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during the DSC analysis.
3.4. In vivo studies
The block of Cutaneous Trunci Muscle Reflex (CTMR) by sub-
cutaneous injection of the given concentration of anesthetic in 0.6 mL
solution was used as a model of infiltration anesthesia in rats. The in-
jections were done under the dorsal surface of the thoracolumbar re-
gion and the local anesthetic effect was quantitatively evaluated by 6
pinprick tests. The complete absence of 6 responses was defined as
100% CTMR block (i.e. 100% of maximum possible effect, MPE). The
pinprick tests were applied every 15min until full CTMR recovery.
In order to evaluate the dose–effect response of the drug, different
prilocaine.HCl concentrations were initially tested (Fig. 4). A 0.05%
drug concentration produced a small block of CTMR (∼30% MPE)
15min after administration, which disappeared after only 45min. On
the contrary, a 0.1% drug concentration induced a significant CTMR
blockage (∼85–90% MPE) between 15 and 60min after administra-
tion, still significant after 90min (MPE∼ 40%). The best results, as
expected, were obtained with the highest drug concentrations of 0.3%
and 0.5%, which produced similar effects, both almost fully blocking
the CTMR (∼85–100% MPE) between 15 and 75min after adminis-
tration, and allowing maintenance of a significantly high block
(∼40–60% MPE) up to 105min, while the effect vanished at 2 h. The
injection of vehicle alone (pH 7.4 phosphate buffer solution, PBS) did
not produce any effect.
Fig. 5 shows a comparison between the effects of prilocaine.HCl at
0.1% and 0.3% and those induced by the same drug concentrations
formulated as prilocaine base loaded in PLGA microparticles. As it
appears evident, the administration of the base form of the drug as
PLGA microparticle formulation gave rise to a clear improvement of its
therapeutic efficacy, in terms of both intensity and duration of the
anesthetic effect with respect to the same dose of the hydrochloride salt
aqueous solution. In fact, even though the maximum intensity of the
effect was reached slightly later (45min vs 30min for prilocaine.HCl),
the effect of prilocaine as microparticle formulation was significantly
more intense and more lasting, particularly for the 0.3% concentration
(240 vs 120min for prilocaine.HCl).
These findings were further corroborated by comparing the values
of the areas under the % MPE versus times curves (AUC). In fact, the
AUC of prilocaine as microparticle formulation at the concentration of
0.1% was about 32% higher than that of prilocaine.HCl at the same
concentration and not significantly different (P > .05) from that of
prilocaine.HCl at 0.3%. Moreover, the AUC of prilocaine as micro-
particle formulation at the concentration of 0.3% was about 60% higher
than that of prilocaine.HCl at the same concentration
Finally, in order to exclude any possible influence of the polymer
used for the microparticle formulation on local anesthesia, the effect of
the administration of the polymer without drug (drug-free micro-
particles) was evaluated. Administration of drug-free PLGA micro-
particles did not elicit any effect in rats.
4. Conclusions
A parenteral formulation of prilocaine as free base was successfully
developed by encapsulation of the anesthetic drug into polymeric bio-
compatible and biodegradable microparticles prepared with PLGA by a
double emulsion preparation method. Drug-loaded microparticles ex-
hibited homogeneous dimensions, with mean diameters around 26 µm,
thus being well suitable for subcutaneous injection using a 23G needle.
In vitro drug release tests, carried out under physiological conditions of
temperature and pH, showed that the drug release pattern was
Fig. 4. Normalized mean (± SEM) degree of anesthetic effect (expressed as %
of maximum possible effect MPE) versus time curve achieved by Cutaneous
Trunci Muscle Reflex (CTMR) test. Data were obtained after single-dose sub-
cutaneous injection of 0.6 mL of prilocaine hydrochloride (PRL.HCl) aqueous
solution at different concentrations and of a phosphate-buffered saline as blank
control. *P < .01 and ^P < .05 with respect to the control. Each value re-
presents the mean of 6 rats.
Fig. 5. Normalized mean (± SEM) degree of anesthetic effect (expressed as %
of maximum possible effect MPE) versus time curve achieved by Cutaneous
Trunci Muscle Reflex (CTMR) test. Data were obtained after single-dose sub-
cutaneous injection of 0.6mL aqueous solution containing 0.1% (upper dia-
gram) or 0.3% (bottom diagram) prilocaine as hydrochloride salt (PRL.HCl) or
as free base loaded in PLGA microparticles (PRL-MP), and of a phosphate-
buffered saline as blank control. *P < .01 and ^P < .05 with respect to the
control. Each value is the mean of 6 rats.
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characterized by an initial rapid release of the drug (about 80% of
prilocaine released within the first 24 h), followed by a slow release
phase, reaching 100% release after about 72 h. DSC studies allowed to
exclude any possible negative effect on the microparticles formulation
stability due to the preparation protocol, and evidenced a lowering of
the PLGA glass transition temperature, due to a plasticizing effect of
prilocaine towards the polymer, as well as the disappearance of the
drug melting peak, attributed to its almost complete dissolution into the
polymer matrix (Delplace et al., 2012; Gasmi et al., 2015).
In vivo studies performed in rats proved the actual significant im-
provement in therapeutic efficacy obtained by encapsulation of prilo-
caine free base in PLGA microparticles, in terms of both intensity and
duration of the anesthetic effect. In particular administration of prilo-
caine base at 0.3% as microparticle formulation enabled an increase of
1.6 times of AUC and 2 times of duration of the anesthetic effect
compared to the administration of the same dose of the hydrochloride
salt aqueous solution.
In conclusion, entrapment in PLGA microparticles allowed the de-
velopment of a parenteral formulation of prilocaine free base in an
aqueous vehicle, and proved to be an excellent and simple strategy not
only for overcoming problems of poor drug stability, but also for en-
hancing its therapeutic efficacy. Therefore, the developed formulation
represents a good choice to replace the use of vasoconstrictors for the
prolongation of the drug-anesthetic effect.
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